I know, I've written about this several times in the last 6 weeks, but it's worth putting out there one more time, because it's become even more clear how significant it is.
At this year's ASCO conference, German researchers showed updated results for their long-term study of Bendamustine + Rituxan vs. CHOP + Rituxan for first treatment of Follicular NHL patients. B+R results in longer progression-free survival with much less toxicity, when compared to CHOP + R. It's a big deal.
This was discussed once again in The ASCO Post, earlier this month.
When you read the piece linked above, be sure to click on the Figure on the left, too, for some cautions. Still no change in overall survival, and the results have not yet been published (and thus not yet peer-reviewed by other lymphoma experts). But that doesn't mean we can't get excited about it anyway. Even if this is the fifth time you've heard about it....
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment